Q3 2025 Earnings Call Today's Presenters © Copyright 2025 Workhorse. Confidential & Proprietary | 2 Rick Dauch CEO, Workhorse Bob Ginnan CFO, Workhorse November 11, 2025 Stan March VP, Corporate Development, Workhorse • 30+ years of automotive industry experience • 19 years serving in CEO roles • Multiple public and private board memberships • 25+ years of senior finance and leadership experience • Refined capital structures for firms in multiple industries • Executed multiple accounting and information tec ...

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a GAAP net loss of $346.8 million, or $0.84 per basic and diluted share, reflecting early-stage corporate expenses and non-cash items [16][17] - General and administrative expenses totaled $37.8 million, including $24.8 million in share-based compensation [16] - The company ended the quarter with $183 million in cash and cash equivalents, including $99.3 million of restricted cash [18] Business Line Data and Key Metrics Changes - The company remains pre-revenue while advancing Project Matador, expecting to begin generating revenue in 2026 [16] - The first gigawatt of gross capacity is projected to generate approximately $1.5 billion in annualized revenue and about $1 billion in net operating income [14] Market Data and Key Metrics Changes - The company has secured or placed under letter of intent approximately 2.2 gigawatts of gas-fired generation, including nine industrial turbines [12] - The demand for power is expected to increase, with the company actively discussing additional tenants for future capacity [27][56] Company Strategy and Development Direction - The company aims to build a hypergrid campus integrating nuclear, natural gas, solar, and storage to serve high-density AI compute loads [12] - The strategy includes long-term triple-net leases with investment-grade tenants, providing a stable revenue model [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of Project Matador, highlighting strong partnerships and operational milestones achieved [10][11] - The company views the current geopolitical landscape, particularly the competition in AI and energy, as a significant driver for its business model [6][7] Other Important Information - The company completed its IPO, raising approximately $785 million in gross proceeds, which will fund the initial phase of Project Matador [19][20] - The company has a strong focus on supply chain management and labor availability in the Panhandle region, which is crucial for project execution [39][40] Q&A Session Summary Question: Clarification on the $150 million advance agreement - Management indicated that the $150 million advance is a sign of good faith and commitment from the first tenant, reflecting their seriousness in the negotiations [24][25][26] Question: Timeline for tenant contracts and negotiations - Management confirmed that the next step is to finalize the lease agreement with tenant one and that discussions with other potential tenants are ongoing [26][27] Question: Visibility into supply chain and labor for 2026 - Management expressed confidence in the supply chain and labor availability, emphasizing proactive measures to secure long lead-time items [33][39] Question: Impact of recent government nuclear deals - Management noted that the recent government nuclear deal supports their objectives and positions them favorably within the industry [36][38] Question: Financing for solar and battery energy storage systems (BESS) - Management clarified that the financing for BESS will be part of the overall project finance, with ongoing discussions with tenant one regarding specifications [41][42] Question: Campus expansion plans - Management confirmed that the 2,000-acre campus expansion is under contract and will be recommended to the board for approval, reflecting confidence in future capacity needs [44][45]

RadNet Investor Day 2025 Summary Company Overview - **Company**: RadNet - **Event**: Investor Day 2025 - **Location**: Nasdaq Marketplace, New York City Key Industry Insights - **Healthcare Transition**: The healthcare industry is shifting from hospital-centric models to ambulatory settings, driven by patient preferences for lower-cost and more efficient care options post-COVID [11][12] - **Technology Integration**: RadNet is focusing on integrating technology, particularly AI, to enhance diagnostic accuracy and efficiency, moving from reactive detection to proactive prevention [13][14] Financial Performance - **Record Quarter**: RadNet reported a record third quarter with a revenue growth of 13.4% year-over-year and EBITDA growth of 15.2% [20][21] - **Digital Health Growth**: The digital health division experienced significant growth of 51.6% compared to the previous year [20] - **Strong Balance Sheet**: The company ended the quarter with over $800 million in cash and low leverage, indicating strong financial health [22] Operational Highlights - **Procedure Volume Growth**: MRI procedures grew by 14.8% and CT procedures by 9.4% year-over-year, with PET/CT showing over 21% growth [21][22] - **Capacity Expansion**: RadNet is actively opening new DeNovo centers and has plans for 11 additional projects next year [23][24] - **Acquisition Strategy**: The company is positioned to consolidate within the industry, leveraging scale to become a low-cost provider [24] Technological Innovations - **AI in Imaging**: RadNet is utilizing AI tools to improve workflow efficiency and patient outcomes, particularly in neuroimaging and breast cancer detection [30][39] - **Lung Cancer Screening**: The company is involved in lung cancer screening initiatives in the UK, demonstrating the effectiveness of AI in improving diagnostic accuracy and efficiency [40][48] Clinical Advancements - **Neuroimaging**: AI innovations are enhancing early disease detection and workflow efficiency in neuroimaging, with significant increases in MRI brain volumes [30][34] - **Breast Cancer Detection**: RadNet is implementing advanced imaging techniques and AI to improve early detection of breast cancer, addressing the rising incidence among younger women [54][65] - **Prostate Cancer Screening**: The company is promoting combined PSA and MRI screening to reduce mortality rates in prostate cancer [66][68] Market Opportunities - **Population Health Focus**: RadNet aims to lead in population health by diagnosing diseases earlier, thus expanding its total addressable market [28][39] - **Lung Cancer Screening Market**: The UK lung cancer screening program is expected to grow significantly, with RadNet positioned to capture a large share of this market [49][52] Conclusion - RadNet is strategically positioned to leverage technological advancements and operational efficiencies to drive growth in the evolving healthcare landscape, focusing on early disease detection and improved patient outcomes while maintaining strong financial health and expanding market presence.

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $341.1 million, exceeding expectations due to higher average day rates and better utilization, with a gross margin of 48%, which was 200 basis points better than guidance [7][34] - Free cash flow generated in Q3 was $83 million, bringing total free cash flow for the first nine months of 2025 to nearly $275 million [8] - The company ended Q3 with a net debt to EBITDA ratio of 0.4 times, indicating a strong leverage position [18] Business Line Data and Key Metrics Changes - Production support, comprising roughly 50% of the business, remains steady, supported by current commodity prices and the deployment of FPSO units [12] - The EPCI and offshore construction segment is seeing an increase in demand, with backlog converting into vessel demand expected to strengthen in 2026 and 2027 [13] - Average day rates for Q3 were $22,798, which was 2% lower than Q2, while active utilization increased from 76.4% to 78.5% [34] Market Data and Key Metrics Changes - The offshore vessel market is expected to see a recovery in drilling activity towards the end of 2026, with a projected increase in capital expenditures to address hydrocarbon supply deficits [11] - In Europe, day rates faced pressure, particularly in the UK, but utilization improved across the region [26] - The Middle East saw strengthening vessel demand and day rates, driven by EPCI contractors [28] Company Strategy and Development Direction - The company is focused on capital allocation, with a $500 million share repurchase authorization in place, but did not repurchase shares in the last quarter due to competing priorities [8][9] - The strategy includes potential M&A opportunities, with a willingness to add leverage if cash flows allow for quick deleveraging [10][19] - The company remains optimistic about the long-term outlook for the offshore vessel industry and aims to deploy capital effectively to drive shareholder value [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the offshore vessel market's recovery, anticipating an uptick in drilling activity in 2026 and beyond [11][25] - The company noted that macro uncertainties and supply chain bottlenecks have impacted near-term drilling activity but expects a return to stronger demand [11] - Management highlighted the importance of maintaining utilization and day rates in the face of potential softness in the drilling market [14] Other Important Information - The company successfully refinanced its debt, resulting in a charge of $27.1 million related to early extinguishment of debt [41] - Drydock costs for 2025 are projected to be $105 million, with an increase to $124 million expected for 2026 [42][44] - The company is optimistic about the potential recovery in the offshore market, particularly in regions like Africa and the Americas [29][30] Q&A Session Summary Question: Thoughts on the production support market and rig levels needed for pricing leverage - Management expects pricing leverage to return sooner due to increasing activity in FPSOs and EPCI, along with vessel attrition over the past two years [49][50] Question: Insights on capital allocation and M&A opportunities - Management acknowledged having material nonpublic information during the quarter, which influenced the decision not to repurchase shares [52] Question: Guidance for 2026 and regional exposure - Management provided guidance for 2026, indicating confidence in achieving at least the same performance as 2025, with Africa and Asia having more exposure to open capacity [58][59] Question: Impact of maintenance on utilization and revenue expectations - Management indicated that the revenue for 2026 is expected to be fairly even throughout the year, with potential upside if drilling activity strengthens [90]

Summary of Ralliant's Earnings Call Company Overview - **Company**: Ralliant - **Industry**: Advanced Industrial Technology - **Key Executives**: Tami Newcombe (CEO), Neil Reynolds (CFO) - **Recent Milestone**: First earnings call as an independent public company after spinning off from Fortive on June 30th, 2023 [3][4] Core Points and Arguments Business Structure and Strategy - Ralliant has established a leadership team with deep industry knowledge and operational rigor, emphasizing stability and expertise [4][5] - The company introduced a profitable growth strategy, focusing on long-term growth vectors that align with secular trends [5][11] - Ralliant operates in two segments: Sensors and Safety Systems (60% of business) and Test and Measurement (40% of business) [8][9] Customer Base and Market Position - Ralliant serves approximately 90,000 customers globally, including major industrial and technology companies [6][8] - The company differentiates itself through precision engineering and proprietary manufacturing processes [6][7] Growth Vectors - **Defense Sector**: Anticipating a surge in demand, with a backlog nearly double the annual revenue for 2026-2028 [16][19] - **Power Grid**: Significant opportunities exist due to aging infrastructure, with 70% of the US grid over 25 years old [17][18] - **Electrification**: Growth in sectors related to electronics and precision instruments [11] Financial Performance and Projections - Ralliant reported $2 billion in revenue last year with 7,000 employees [8] - The company aims for a growth rate of 3%-5% over the next few years, with certain segments like defense and power grid showing higher growth potential [30] - The EBITDA margin for Sensors and Safety Systems is in the high 20s, while Test and Measurement targets mid-teens to low 20s [37][38] Challenges and Opportunities - The Test and Measurement segment has faced challenges but is expected to recover with new product launches and improved market conditions [31][36] - The company is adapting to changes in the China market and exploring opportunities in India and Southeast Asia [36] Capital Allocation and Investment Strategy - Ralliant plans to increase capital expenditures from 2% to 2%-3% of revenue to support growth initiatives [22] - The focus will be on organic growth, returning capital to shareholders, and potential tuck-in acquisitions [23] Additional Important Insights - Ralliant's business model is diversified both by end markets and geography, with a balanced presence in the US and international markets [7][8] - The company is committed to enhancing its service offerings by transitioning from individual sensor products to comprehensive solution packages that include analytics and software [26] - The leadership emphasizes a disciplined approach to capital allocation and operational efficiency to drive long-term value creation [11][22] This summary encapsulates the key points discussed during Ralliant's earnings call, highlighting the company's strategic direction, market opportunities, and financial outlook.

Honeywell Aerospace FY Conference Summary Company Overview - **Company**: Honeywell International (NasdaqGS: HON) - **Division**: Honeywell Aerospace - **CEO**: Jim Currier, appointed in August 2023 - **Spin-off**: Planned spin-off of Boeing as an independent entity in 2026 [2][3] Key Industry Insights Aerospace Market Position - Honeywell Aerospace is set to become one of the largest pure-play aerospace suppliers post-spin-off, allowing for focused strategic decisions [3][4] - The company aims to leverage its investment-grade balance sheet for future growth opportunities [4][5] Market Segmentation - Honeywell serves multiple end markets: commercial air transport, business aviation, and defense space [9][10] - The portfolio includes electronic solutions, digital power systems, and control systems, covering a wide range of aircraft components [10][11] Financial Performance - The company has maintained a strong operating system focused on productivity, efficiency, and margin expansion, leading to consistent margin performance [12][13] - Investments in new technologies and products are at or above industry peers, with a focus on sustaining a long-term growth profile [13][14] Market Dynamics Business Jet Market - Post-COVID, business jet flight hours surged to 20% above pre-pandemic levels but are expected to normalize to low single-digit growth [18][19] - The air transport market shows stronger growth potential, particularly in regions like Europe, the Middle East, and Asia Pacific [20][21] Aftermarket Growth - Honeywell has outpaced the aftermarket growth through investments in retrofitted modifications, which account for about 10% of total revenue [23][24] - The company has a significant software engineering workforce (approximately 11,000 engineers) to enhance value-added offerings [25][26] Supply Chain Management - The supply chain is bifurcated into electronics and mechanical segments, with electronics fully recovered while mechanical faces ongoing constraints [28][29] - Honeywell has invested over $1 billion since 2021 to enhance supply chain capacity and resilience [30][31] Defense Sector Insights - 60% of Honeywell's business is commercial, while 40% is defense, with 75% of defense revenue coming from domestic sources [34][35] - The company is well-positioned to capitalize on increased defense spending, particularly in NATO and the Indo-Pacific regions [38][39] Mergers and Acquisitions - Recent acquisitions have integrated well, exceeding performance expectations, and M&A will be a critical part of Honeywell's growth strategy moving forward [47][48] - The company has a robust pipeline of potential acquisition targets [49][50] Backlog and Future Outlook - Honeywell Aerospace has an all-time high backlog of $39 billion and a book-to-bill ratio of 1.2, indicating strong future growth potential [51][52] - The company anticipates continued growth in air transport and defense sectors, despite normalization in the business aviation market [53] Advanced Air Mobility - Honeywell has established a dedicated business unit for advanced air mobility, focusing on integrating new technologies and securing positions across various platforms [55][56] - Certification of new products is expected, with significant adoption anticipated by the mid-2030s [60][61] This summary encapsulates the key points discussed during the Honeywell Aerospace FY Conference, highlighting the company's strategic direction, market dynamics, and future growth opportunities.

GoGold Resources Conference Call Summary Company Overview - GoGold Resources operates in the mining sector, specifically focusing on silver and gold production in Mexico. The company has a history of building and operating mines, with significant experience in the region [1][2]. Financial Position - GoGold has a strong financial position with $141 million in cash and no debt [3][4]. - The company generates approximately $3 million in free cash flow per month from its tailings reprocessing operation, totaling around $40 million annually [3]. Key Projects Las Ricos Project - The Las Ricos project is a significant focus for GoGold, located in Jalisco, Mexico, with a strong potential for silver production [4][5]. - The project has 285 million ounces of silver-equivalent resources after extensive drilling [5]. - A final feasibility study has been completed, and the company is in the execution phase, having awarded contracts for engineering and construction [6][7]. Production Goals - The company aims to produce 9 million ounces of silver annually, with Las Ricos South expected to contribute an additional 7.2 million ounces [9]. - The all-in sustaining costs for production are projected to be around $12 per ounce, indicating a high-margin operation [9][11]. Construction and Development Plans - The construction of Las Ricos South is expected to take 24 months, with the first doré bar pour anticipated at the end of this period [7][11]. - Plans are in place to begin drilling at Las Ricos North to advance the project further [8][11]. Community and Environmental Relations - GoGold emphasizes strong community relations and environmental standards, which are crucial for obtaining permits in Mexico [12][13]. - The company has successfully engaged with local communities, receiving positive feedback regarding its projects [13][14]. Regulatory Environment - The permitting process in Mexico is community-focused, with the government actively seeking community input on mining projects [12][14]. - GoGold is optimistic about receiving necessary permits by the end of the year, although holiday delays may push this into the new year [14]. Operational Practices - GoGold employs best practices in tailings management, utilizing dry stacked tails and recycling water to minimize environmental impact [22][23]. - The company has a history of addressing old mining liabilities and ensuring compliance with modern environmental standards [23]. Future Outlook - GoGold is positioned for growth with plans to expand production capacity significantly over the next few years, aiming to become a top silver producer [11]. - The company is exploring financing options to support its growth while maintaining flexibility in capital structure [10].

Cardinal Health (NYSE: CAH) 2025 Conference Summary Company Overview - **Company**: Cardinal Health - **Date**: November 11, 2025 - **Key Speakers**: Aaron Alt (CFO), Matt Sims (Head of IR) Key Points Financial Performance - Cardinal Health reported strong Q1 results with all five operating segments achieving double-digit profit growth, particularly in the pharma business, which saw a profit increase of 26% [2][3][4] - The company raised its adjusted EPS guidance to $9.65-$9.85, reflecting a year-over-year growth of 17%-20% [4][5] Business Segments - **Pharma Business**: Strong demand and execution, particularly in specialty distribution, contributed significantly to profit growth [2][3] - **Other Business**: The aggregation of smaller businesses (Nuclear Precision Health, At Home, OptiFreight Logistics) saw a profit growth of 60%, partly due to the acquisition of ADSG [3][4] - **Global Medical Products and Distribution (GMPD)**: Experienced revenue growth with the Cardinal Health brand business growing at 6% for two consecutive quarters [4][5][56] Customer Onboarding and Growth Strategy - Cardinal Health onboarded $10 billion in new business in the latter half of the previous year and is on track to onboard an additional $7 billion in the first half of the current year [5][12] - The company is focusing on investing in new customers and enhancing its MSO platforms to drive future growth [5][6] Market Dynamics and Demand - Demand across all segments exceeded expectations, with notable growth in generics and specialty products [9][10] - The company noted a consistent market dynamic, indicating no dislocation between buying and selling, which contributed to strong quarterly results [10][11] Specialty Business Focus - Cardinal Health emphasizes its strength in "otherologies" (rheumatology, urology, gastroenterology) rather than oncology, which is a key differentiator in its specialty business strategy [19][20] - The company aims to leverage its distribution capabilities and technology to enhance partnerships with healthcare providers in these specialty areas [25][26] Competitive Landscape - The medical products business is undergoing competitive changes, with Cardinal Health focusing on improving its GMPD segment to maintain market share against competitors like Medline and McKesson [56][59] - The company is actively seeking opportunities arising from industry transitions, such as acquisitions and partnerships, to enhance its competitive position [60] Operational Efficiency - Cardinal Health is investing in automation and optimizing its distribution network to improve operational efficiency and reduce costs [36][37] - The company is committed to maintaining high service levels while managing costs effectively [37][39] Future Outlook - The company anticipates continued growth in its nuclear precision health business, projecting a long-term profit growth of 10% [74][75] - Cardinal Health remains confident in its long-term guidance, citing its essential role in the American healthcare system and the ongoing demand for its services [49][50] COVID-19 Impact - COVID-19 was noted as a slight headwind in Q1, but overall demand growth offset this impact [78][79] - The company expects COVID-related profits to continue declining, with a focus on broader market dynamics moving forward [79][80] Conclusion Cardinal Health's strong financial performance, strategic focus on specialty and otherologies, and commitment to operational efficiency position the company well for future growth in a competitive healthcare landscape. The ongoing investments in customer onboarding and technology enhancements are expected to drive continued success.

Summary of Viatris Conference Call Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Event**: UBS Healthcare Conference - **Date**: November 11, 2025 Key Updates and Financial Performance - Viatris reported a positive momentum in business with an expected operational revenue growth of **2-3%** for 2025, excluding Indor [4][80] - The company is on track to return over **$1 billion** to shareholders, including **$500 million** in share repurchases for the year [4][80] New Product Launches - Anticipated new product revenue is projected to be in the range of **$450 million to $550 million** annually, driven by existing products and upcoming launches [6][4] - Key products contributing to this revenue include: - **Iron sucrose** - **Glucagon** - **Paclitaxel** - Upcoming launches: **Liraglutide**, **Effexor GAD**, **Sotagliflozin** [6][4] Geographic Performance - **North America**: - Experienced competition in generic products, particularly **XULANE LO** [17][22] - Decline primarily attributed to the impact of Indor [19][22] - Strong double-digit growth noted in products like **Breyna** and **Uptravi** [22][22] - **Emerging Markets**: - Strong growth driven by established brand business, particularly in **Turkey**, **Mexico**, and **emerging Asia** [23][23] - Stabilization of lower-margin ARV products has supported growth in the generics business [23][23] - **Japan**: - Facing normal price regulations but focusing on adding innovative assets to stabilize and grow the business [26][26] - Recent acquisition of **Pitolisant** and **Spidea** expected to enhance the portfolio [26][26] - **China**: - Achieved **9% operational growth** driven by a diversified commercial model and strong brand demand [28][28] - Over **10,000 customers** across various channels, with expectations for low to mid-single-digit growth over time [31][31] Pipeline and Future Products - Excitement around **fast-acting meloxicam** as a non-opioid alternative for acute pain management, targeting a launch in the second half of **2026** [34][41] - Anticipated FDA filings for several products, including **Effexor GAD** and **Salatogrel**, with enrollment for Salatogrel on track to complete by the end of **2026** [51][52] Indor Remediation and Strategic Review - Progress on remediation efforts for Indor, with operational readiness for reinspection expected in **2026** [54][54] - An enterprise-wide strategic review initiated to ensure sustainable growth, with details expected in **Q1 2026** [60][60] Capital Allocation Strategy - Viatris maintains a balanced capital allocation strategy, focusing on business development and capital return, with a **50/25/25** framework [71][71] - The company is looking for opportunities to invest in durable, higher-margin innovative assets, particularly in the U.S. market [73][73] Conclusion - Viatris is optimistic about its position going into **2026**, with a focus on executing its strategic priorities, enhancing its product pipeline, and addressing challenges in various markets [80][80]

Summary of Spyre Therapeutics Conference Call Company Overview - **Company**: Spyre Therapeutics (NasdaqGS:SYRE) - **Focus**: Development of indication-leading products for autoimmune diseases, particularly inflammatory bowel disease (IBD) and rheumatic diseases [2][3] Core Points and Arguments Product Development - Spyre is developing three long-acting antibodies targeting alpha-4 beta-7, TL1A, and IL-23, which have over three times the half-life of first-generation products, potentially leading to greater convenience and efficacy [2][3] - The company believes that combination therapies will significantly improve efficacy in IBD, as no single mechanism has proven effective enough to cure the disease [3][4] - The Vega study by J&J demonstrated that combination therapies can nearly double clinical remission rates in naive patients, supporting the efficacy of multi-target approaches [10][11] Market Position and Strategy - Spyre's approach focuses on co-formulations rather than bi-specific antibodies, as the latter may carry higher risks and less effective targeting in IBD [6][9] - The company aims to achieve a clinically meaningful 10-point delta in efficacy compared to existing monotherapies, which could position their products as mega blockbuster drugs [12][14] Pipeline and Future Expectations - Spyre has generated Phase I data for its alpha-4 beta-7, TL1A, and IL-23 antibodies, with expectations of at least comparable efficacy to first-generation products [23][28] - The company has a robust financial position with nearly $800 million on the balance sheet, allowing for strategic flexibility and the potential to pursue multiple indication-leading products across IBD and rheumatic diseases [47][48] Competitive Landscape - The company is aware of the competitive landscape, with other firms entering the TL1A space, but believes its first-mover advantage and product properties will maintain its lead [41][46] - The market for rheumatic diseases is estimated at $30 billion, with Spyre's products potentially offering a significant convenience advantage over existing therapies [39] Important but Overlooked Content - The design of Spyre's Phase II studies aims to address the contribution of components in combination therapies, which is a novel approach in IBD [21][18] - The company is also exploring the potential of TL1A in rheumatic diseases, supported by genetic and clinical evidence, which could lead to a significant market opportunity [38][39] - The preference for injectable therapies over daily oral medications among patients may favor Spyre's long-acting injectable products [50][51] This summary encapsulates the key insights from the conference call, highlighting Spyre Therapeutics' strategic focus, product development, market positioning, and future expectations in the context of autoimmune disease therapies.